Midas Letter Live- Strainprint CTO on Cannabis At Work Partnership

Written by Strainprint

Strainprint’s CTO, David Berg, recently sat down with the Midas Letter Live to talk about our partnership with Cannabis At Work.

About

Midas Letter is the journal of “best-in-class” companies in all sectors. Publisher James West is a recognized authority on investing in the emerging company segment having been a regularly featured guest on Business News Network, CNBC, Bloomberg, Reuters, CTV and most recently as investment columnist in the Financial Post.

Cannabis & Opioids: An Interview with Dr. Peter Grinspoon

Coinciding with the adult use legalization of cannabis across North America, an opioid epidemic has emerged. It is estimated that more than 130 people die each day due to opioid overdose in the United States alone, according to the U.S. Department of Health and Human Services (HHS). The organization reported that, in 2017, nearly 50,000 Americans died […]

Understanding Terpenes: Camphene

Camphene, sometimes called comphene, is one of more than 200 terpenes discovered to date in hemp and cannabis. Terpenes are aromatic molecules once thought to convey only aroma and, from an evolutionary functional perspective, to protect a plant from pests and predators. In recent years, however, much clinical research, in addition to anecdotal evidence, has […]

Understanding Terpenes — Beta-Caryophyllene

Welcome to the Strainprint Community Understanding Terpenes Series. Before diving into the details behind beta-caryophyllene (BCP, caryophyllene, or β-caryophyllene), the molecule produced by cannabis known for its categorization as both a terpene and a cannabinoid that provides pain killing and anti-inflammatory benefits, it behooves readers to develop a solid understanding of terpenes as a category of wellness molecule. Patients […]